Allopurinol attenuates L-NAME induced cardiomyopathy comparable to blockade of angiotensin receptor

Histology and Histopathology

Volumn 23, Issue 10, 2008, Pages 1241-1248

  Kasal, Daniel Arthur B ^a   Neves, Mario Fritsch ^a   Oigman, Wille ^a   Mandarim de Lacerda, Carlos A ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Allopurinol; Arterial hypertension; Cardiac remodeling; L NAME; Olmesartan

Indexed keywords

ALLOPURINOL; ANGIOTENSIN RECEPTOR; N(G) NITROARGININE METHYL ESTER; OLMESARTAN; XANTHINE OXIDASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE; URIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOMYOPATHY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART PROTECTION; HYPERTENSION; MALE; MONOTHERAPY; NONHUMAN; PRIMARY PREVENTION; PROTEIN FUNCTION; RAT; ANIMAL; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HEART MUSCLE; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TIME; WISTAR RAT;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

ALLOPURINOL; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HYPERTENSION; IMIDAZOLES; MALE; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; RATS; RATS, WISTAR; TETRAZOLES; TIME FACTORS; URIC ACID; VENTRICULAR REMODELING; XANTHINE OXIDASE;

EID: 54449092123     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Akishita M., Nagai K., Xi H., Yu W., Sudoh N., Watanabe T., Ohara-Imaizumi M., Nagamatsu S., Kozaki K., Horiuchi M. and Toba K. (2005). Renin-angiotensin system modulates oxidative stress-induced endothelial cell apoptosis in rats. Hypertension 45, 1188-1193.
2. Berry C.E. and Hare J.M. (2004). Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J. Physiol. 555, 589-606.
3. Brousil J.A. and Burke J.M. (2003). Olmesartan medoxomil: an angiotensin II-receptor blocker. Clin. Ther. 25, 1041-1055.
4. Cappola T.P., Kass D.A., Nelson G.S., Berger R.D., Rosas G.O., Kobeissi Z.A., Marbán E. and Hare J.M. (2001). Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104, 2407-2411.
5. El Mabrouk M., Singh A., Touyz R.M. and Schiffrin E.L. (2000). Antiproliferative effect of L-NAME on rat vascular smooth muscle cells. Life Sci. 67, 1613-1623.
6. Engberding N., Spiekermann S., Schaefer A., Heineke A., Wiencke A., Muller M., Fuchs M., Hilfiker-Kleiner D., Hornig B., Drexler H. and Landmesser U. (2004). Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 110, 2175-2179.
7. Fiordaliso F., Li B., Latini R., Sonnenblick E.H., Anversa P., Leri A. and Kajstura J. (2000). Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II- dependent. Lab. Invest. 80, 513-527.
8. George J., Carr E., Davies J., Belch J.J. and Struthers A. (2006). High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114, 2508-2516.
9. Gundersen H.J.G. and Osterby R. (1981). Optimizing sampling efficiency of stereological studies in biology: or 'do more less well!' J. Microsc.121, 65-73.
10. Izuhara Y., Nangaku M., Inagi R., Tominaga N., Aizawa T., Kurokawa K., van Ypersele de Strihou C. and Miyata T. (2005). Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J. Am. Soc. Nephrol. 16, 3631-3641.
11. Katoh M., Egashira K., Usui M., Ichiki T., Tomita H., Shimokawa H., Rakugi H. and Takeshita A. (1998). Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ. Res. 83, 743-751.
12. Laakso J., Vaskonen T., Mervaala E., Vapaatalo H. and Lapatto R. (1999). Inhibition of nitric oxide synthase induces renal xanthine oxidoreductase activity in spontaneously hypertensive rats. Life Sci. 65, 2679-2685.
13. Levy B.I. (2004). Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 109, 8-13.
14. Linardi A., Panunto P.C., Ferro E.S. and Hyslop S. (2004). Peptidase activities in rats treated chronically with N(omega)-nitro-L-arginine methyl ester (L-NAME). Biochem. Pharmacol. 68, 205-214.
15. Mandarim-de-Lacerda C.A. (2003). Stereological tools in biomedical research. An. Acad. Bras. Cienc. 75, 469-486.
16. Mandarim-de-Lacerda C.A. and Pereira L.M. (2001). Volume-weighted mean nuclear volume and numerical nuclear density in the cardiomyocyte following enalapril and verapamil treatment. Virchows Arch. 438, 92-95.
17. Mazzali M., Hughes J., Kim Y.G., Jefferson J.A., Kang D.H., Gordon K.L., Lan H.Y., Kivlighn S. and Johnson R.J. (2001). Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38, 1101-1106.
18. Mellin V., Isabelle M., Oudot A., Vergely-Vandriesse C., Monteil C., Di Meglio B., Henry J.P., Dautreaux B., Rochette L., Thuillez C. and Mulder P. (2005). Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur. Heart J. 26, 1544-1550.
19. Moncada S. and Higgs A. (1993). The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329, 2002-2002-2012.
20. Moreno H. Jr, Metze K., Bento A.C., Antunes E., Zatz R. and de Nucci G. (1996). Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. Basic Res. Cardiol. 91, 248-255.
21. Neumann J. (2003). A renaissance of positive inotropic interventions to treat heart failure? Cardiovasc. Res. 59, 534-535.
22. Niu X.F., Smith C.W. and Kubes P. (1994). Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. Circ. Res. 74, 1133-1140.
23. Ono Y., Ono H., Matsuoka H., Fujimori T. and Frohlich E.D. (1999). Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR. Hypertension 34, 609-616.
24. Pereira L.M. and Mandarim-de-Lacerda C.A. (1999). Quantitative study of myocardial microcirculation in arterial hypertension due to progressive inhibition of NO synthesis. Arq. Bras. Cardiol. 73, 407-418.
25. Pereira L.M., Bezerra D.G. and Mandarim-de-Lacerda C.A. (2004). Aortic wall remodeling in rats with nitric oxide deficiency treated by enalapril or verapamil. Pathol Res Pract 200, 211-217.
26. Pessanha M.G. and Mandarim-de-Lacerda C.A. (2000). Influence of the chronic nitric oxide synthesis inhibition on cardiomyocytes number. Virchows Arch. 437, 667-674.
27. Saavedra W.F., Paolocci N., St John M.E., Skaf M.W., Stewart G.C., Xie J.S., Harrison R.W., Zeichner J., Mudrick D., Marban E., Kass D.A. and Hare J.M. (2002). Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ. Res. 90, 297-304.
28. Sanada S., Kitakaze M., Node K., Takashima S., Ogai A., Asanuma H., Sakata Y., Asakura M., Ogita H., Liao Y., Fukushima T., Yamada J., Minamino T., Kuzuya T. and Hori M. (2001). Differential subcellular actions of ACE inhibitors and AT(1) receptor antagonists on cardiac remodeling induced by chronic inhibition of NO synthesis in rats. Hypertension 38, 404-411.
29. Scherle W. (1970). A simple method for volumetry of organs in quantitative stereology. Mikroskopie 26, 57-60.
30. Sladek T., Gerova M., Znojil V. and Devat L. (1996). Morphometric characteristics of cardiac hypertrophy induced by long-term inhibition of NO synthase. Physiol. Res. 45, 335-338.
31. Sterio D.C. (1984). The unbiased estimation of number and sizes of arbitrary particles using the disector. J. Microsc. 134 (Pt 2), 127-136.
32. Struthers A.D., Donnan P.T., Lindsay P., McNaughton D., Broomhall J. and MacDonald T.M. (2002). Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 87, 229-234.
33. Takemoto M., Egashira K., Tomita H., Usui M., Okamoto H., Kitabatake A., Shimokawa H., Sueishi K. and Takeshita A. (1997). Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 30, 1621-1627.
34. Terada L.S., Piermattei D., Shibao G.N., McManaman J.L. and Wright R.M. (1997). Hypoxia regulates xanthine dehydrogenase activity at pre- and posttranslational levels. Arch. Biochem. Biophys. 348, 163-168.
35. Usui M., Egashira K., Kitamoto S., Koyanagi M., Katoh M., Kataoka C., Shimokawa H. and Takeshita A. (1999). Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. Hypertension 34, 546-551.
36. Usui M., Egashira K., Tomita H., Koyanagi M., Katoh M., Shimokawa H., Takeya M., Yoshimura T., Matsushima K. and Takeshita A. (2000). Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 101, 305-310.
37. Wallwork C.J., Parks D.A. and Schmid-Schonbein G.W. (2003). Xanthine oxidase activity in the dexamethasone-induced hypertensive rat. Microvasc. Res. 66, 30-37.
38. Weibel E. 1979. Stereological methods. In: Practical methods for biological morphometry. Academic Press. London.
39. Yokoyama H., Averill D.B., Brosnihan K.B., Smith R.D., Schiffrin E.L. and Ferrario C.M. (2005). Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. Am. J. Hyperten. 18, 922-929.
40. Zhang Y., Chan M.M., Andrews M.C., Mori T.A., Croft K.D., McKenzie K.U., Schyvens C.G. and Whitworth J.A. (2005). Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat. Am. J. Hypertens. 18, 910-916.